Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer
Kei Kudo(National Institutes of Health), Christina M. Annunziata(National Institutes of Health)
Cited by 3
Related Papers
Activation of NF-κB Signaling by Inhibitor of NF-κB Kinase β Increases Aggressiveness of Ovarian Cancer
|Cancer Research|2010|115
IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts
|BMC Cancer|2018|27
Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells
|Frontiers in Oncology|2022|24